Skip Navigation

DRUG RECORD

 

DICLOXACILLIN

 



 

OVERVIEW
Dicloxacillin

Dicloxacillin is an oral, second-generation penicillin antibiotic that is used to treat bacterial infections caused by penicillinase-resistant staphylococci.  Dicloxacillin has been linked to rare instances of clinically apparent, idiosyncratic liver injury

 

Background

Dicloxacillin (dye klox' a sil' in) is a second-generation penicillin that is resistant to inactivation by penicillinases and is used to treat infections caused by penicillinase-producing bacteria.  Like other penicillins, dicloxacillin is a beta lactam antibiotic that is believed to act by binding to the bacterial enzyme that is responsible for synthesizing peptidoglycans which are necessary for the intregity of the bacterial cell wall.  Dicloxacillin was approved for use in the United States in 1968 and is still widely used to treat mild to moderate staphylococcal infections.  To reduce development of drug-resistant bacteria, dicloxacillin is recommended to treat or prevent only those infections that are proven or suspected to be caused by penicillinase-producing susceptible bacteria.  Dicloxacillin is available in multiple generic forms as 250 and 500 mg capsules and as a suspension for pediatric use.  The typical dose is 125 to 500 mg every 6 hours.  Common side effects of dicloxacillin include nausea, diarrhea, stomatitis, skin rash and allergic reactions.

 

Hepatotoxicity

Dicloxacillin therapy has not been associated with serum enzyme elevations during treatment but has been linked to rare instances of clinically apparent, cholestatic hepatitis.  The typical time to onset is 1 to 6 weeks and the pattern of serum enzyme elevations is usually cholestatic, although cases with a mixed pattern have also been described.  The injury usually presents with jaundice and pruritus.  Fever, rash and eosinophlia can occur but are not prominent and autoantibodies are rarely detected.  A similar pattern of injury occurs more frequently with flucloxacillin (also called floxacillin) and cloxacillin, oral isoxazolyl penicillins similar in structure and activity to dicloxacillin but never approved for use or available in the United States.  Similar cholestatic hepatitis arising 1 to 6 weeks after starting therapy occurs with other penicillins.

 

Mechanism of Injury

The cause of the idiosyncratic, cholestatic hepatitis following dicloxacillin therapy is not known.  Allergic manifestations (rash, fever and eosinophilia) are not common and the liver injury is usually not accompanied by signs or symptoms of penicillin hypersensitivity.  However, the rapid recurrence of injury with re-exposure suggests a hypersensitivity mechanism perhaps in response to the beta lactam ring.  Injury occurs more frequently in older patients.  Too few cases of dicloxacillin hepatotoxicity have been reported to comment on possible HLA associations, such as the link to HLA-B*5701 which has been made to flucloxacin. 

 

Outcome and Management

In the few cases that have been described, cholestasis has been prolonged, but all patients recovered within 6 to 12 weeks without residual injury.  Re-exposure appears to be associated with recurrence of injury, often with a shortened latency period.  The idiosyncratic liver injury from dicloxacillin has not been linked to acute liver failure, chronic injury or the vanishing bile duct syndrome (although these have been described with flucloxacillin).  Prednisone has been used to treat the cholestatic liver injury, but its effects are unclear while its side effects can be serious.  Patients should be told to avoid re-exposure to the penicillinase-resistant penicillins, including nafcillin and oxacillin.


References

 

References to dicloxacillin-induced liver injury are given in the overview section on Penicillinase-Resistant Penicillins.

 

Drug Class: Penicillin (Penicillinase-Resistant)

 

 

 

 

Top of page


CASE REPORT
Dicloxacillin

Case 1.    Cholestatic hepatitis caused by dicloxacillin. 
[Modified from Kleinman MS, Presberg JE. J Clin Gastroenterol 1986; 8: 77-8]

 

A 56 year old man received a 5-day course of oral dicloxacillin (250 mg four times a day) and 2 weeks later developed gastrointestinal discomfort, followed by fever and then jaundice and itching.  He had a history of hepatitis 22 years ago, but no other significant medical history and had no current risk factors for viral hepatitis.  He took no other medications, had no allergies and drank little alcohol.  On admission his serum bilirubin was 3.8; that later rose (Table).  Eosinophil counts were normal.  Tests for acute hepatitis A and B were negative and abdominal ultrasound was normal.  After several weeks, he began to improve and laboratory abnormalities returned to normal 14 weeks after he had started the course of antibiotics.

 

Key Points

 

Medication:Dicloxacillin
Pattern: Mixed (R=2.6)
Severity: 3+ (Jaundice and hospitalization)
Latency: Two to three weeks
Recovery:Complete in 3 months
Other medications:None

 

Laboratory Values

 

Time After Starting Time After Stopping AST* (U/L) Alk P* (U/L) Bilirubin* (mg/dL) Other
0   Dicloxacillin given for 5 days
3 weeks 2 weeks 225 218 3.8 Eosinophils=487
4 weeks 3 weeks 325 230 8.0  
5 weeks 4 weeks 50 150 10.3  
7 weeks 6 weeks 45 165 11.8  
8 weeks 7weeks 60   9.8  
9 weeks 8 weeks 110   5.0  
10weeks 9 weeks 80 170 3.2  
12 weeks 11 weeks 70 135 1.8  
13 weeks 12 weeks 65 120 1.1  
14 weeks 13 weeks 38 60 0.5  
Normal Values <40 <100 < 1.2  

* Estimates made from Figure 1.

 

Comment

The appearance of jaundice and itching 3 weeks after starting a 5-day course of dicloxacillin with a mixed pattern of serum enzyme elevations (later becoming more cholestatic) is fully compatible with dicloxacillin-induced liver injury.  Recovery was somewhat slow but was complete by 3 months.  Idiosyncratic drug-induced liver injury from dicloxacillin is rare and only isolated case reports have been published.  More common and with a similar pattern of injury are cases of flucloxacillin (which was approved and used in Australia and Europe but not in the United States).  Flucloxacillin hepatotoxicity is characterized by a latency of 2 to 6 weeks (often arising 1 to 3 weeks after stopping therapy) with a cholestatic or mixed enzyme pattern and recovery in 1 to 3 months.  Fatalities and vanishing bile duct syndrome have been reported with flucloxacillin but not with dicloxacillin despite the similarity of the injury caused, probably because dicloxacillin is just much less likely to lead to hepatic injury.

 

Top of page




PRODUCT INFORMATION
Dicloxacillin

 

REPRESENTATIVE TRADE NAMES
Generic

DRUG CLASS
Anti-Infective Agents

COMPLETE LABELING

FDA product labeling at DailyMed, National Library of Medicine, NIH
Dicloxacillin Sodium Product Labeling, Sandoz Inc.

 

Top of page

 

OTHER REFERENCE LINKS
Dicloxacillin
  1. PubMed logoRecent References on Dicloxacillin

  2. Clinical Trials logoTrials on Dicloxacillin

  3. TOXLINE logoTOXLINE Citations on Dicloxacillin

 

Top of page